Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
Having closed Wednesday regular trading down marginally on Thursday, China’s BeiGene shot up 22.9% to $170.00 in after-trading as it announced a strategic collaboration with US biotech giant Amgen. 1 November 2019
Biotechnology
US biotech firm Dicerna Pharmaceuticals yesterday announced a research collaboration and licensing agreement with Swiss pharma giant Roche to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC RNAi platform technology. 1 November 2019
Biotechnology
Genmab, one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire. 1 November 2019
Biotechnology
Third-quarter 2019 sales for US biotech Celgene came in at $4.52 billion, up 16% year-on-year and beating consensus forecasts of $4.41 billion. 1 November 2019
Biotechnology
European Medicines Agency’s safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restrictions on the use of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple sclerosis that is highly active despite adequate treatment with at least one disease-modifying therapy or if the disease is worsening rapidly with at least two disabling relapses in a year and brain-imaging showing new damage. 31 October 2019
Biotechnology
US drugmaker AbbVie is eyeing a second approval for its JAK inhibitor Rinvoq (upadacitinib), just 11 weeks after announcing its first one. 31 October 2019
Biotechnology
Bristol-Myers Squibb was nearly 2% up at midday Thursday after presenting its third-quarter financial results. 31 October 2019
Biotechnology
Japanese drug major Sumitomo Dainippon Pharma and Roivant Sciences, a technology-enabled healthcare company, today announced that they have signed a definitive agreement for the creation of a novel and broad Strategic Alliance and to form a new company (the “New Company”) owned and supported by Sumitomo Dainippon. 31 October 2019
Biotechnology
Privately-held US biotech Pandion Therapeutics and Japanese drugmaker Astellas have announced a collaboration with a potential value of $795 million. 31 October 2019
Biotechnology
German life sciences group Bayer was up more than 2% as Wednesday’s trading day neared its end, after the company presented its third-quarter financial results. 30 October 2019
Biotechnology
The US Food and Drug Administration approved Vumerity (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. 30 October 2019
Biotechnology
Germany’s MorphoSys and Belgium’s Galapagos today announced the end of the clinical development program of MOR106 in atopic dermatitis. 30 October 2019
Biotechnology
The European Medicines Agency has validated the Marketing Authorization Application (MAA) for satralizumab for the treatment of adult and adolescent patients with neuromyelitis optica spectrum disorder (NMOSD), granting it accelerated assessment. 30 October 2019
Biotechnology
The US Food and Drug Administration (FDA) has placed a partial hold on spinal muscular atrophy (SMA) clinical trials for the intrathecal administration of a gene therapy that is already approved as an intravenous treatment. 30 October 2019
Biotechnology
US biotech giant Amgen posted third-quarter 2019 financials after market close on Tuesday that beat expectations, but the stock dipped in after-hours trading, having ended the regular trading session up 1.94% to $208.99. 30 October 2019
Biotechnology
The European Commission has adopted a decision to extend to children five years and older, the existing adult indication for intravenous Benlysta (belimumab) as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity. 30 October 2019
Biotechnology
The number of immuno-oncology (I-O) therapies in clinical development and volume of clinical investigations testing these therapies for the treatment of cancer patients continue to grow, and will undoubtedly fulfill unmet needs in both hematological cancers and solid tumors over the next five to ten years. 30 October 2019
Biotechnology
The European Commission (EC) today approved a new indication for Dupixent (dupilumab) in chronic rhinosinusitis with nasal polyposis (CRSwNP). 29 October 2019
Biotechnology
Merck KGaA and Pfizer’s entry into the PD-L1 space has secured a European Commission approval in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). 29 October 2019
Biotechnology
US biotech Ziopharm Oncology and The University of Texas MD Anderson Cancer Center have announced a new research and development agreement. 28 October 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze